-
M.
Sarfaty,
P.
Hall,
Kelvin
Chan,
K.
Virik,
M.
Leshno,
N.
Gordon,
Assaf
Moore,
V.
Neiman,
E.
Rosenbaum,
D.
Goldstein
(2018)
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
European urology, 74 1
-
G.
Hill,
R.
Barron,
K.
Fust,
M.
Skornicki,
Douglas
Taylor,
M.
Weinstein,
G.
Lyman
(2014)
Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses
Journal of Medical Economics, 17
-
Economic burden of haematological adverse effects in cancer patients: a systematic review
-
J.
Rosenberg,
P.
O’Donnell,
A.
Balar,
B.
McGregor,
E.
Heath,
E.
Yu,
M.
Galsky,
N.
Hahn,
E.
Gartner,
J.
Pinelli,
S.
Liang,
A.
Melhem-Bertrandt,
D.
Petrylak
(2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Journal of Clinical Oncology, 37
-
W.
Wong,
Y.
Yim,
A.
Kim,
M.
Cloutier,
M.
Gauthier-Loiselle,
P.
Gagnon-Sanschagrin,
A.
Guerin
(2018)
Assessment of costs associated with adverse events in patients with cancer
PLoS ONE, 13
-
J.
Bellmunt,
R.
Wit,
D.
Vaughn,
Y.
Fradet,
Jae-Lyun
Lee,
L.
Fong,
N.
Vogelzang,
M.
Climent,
D.
Petrylak,
T.
Choueiri,
A.
Necchi,
W.
Gerritsen,
H.
Gurney,
D.
Quinn,
S.
Culine,
C.
Sternberg,
Yabing
Mai,
C.
Poehlein,
R.
Perini,
D.
Bajorin
(2017)
Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma
The New England Journal of Medicine, 376
-
H.
Henk,
Connie
Chen,
Á.
Benedict,
J.
Sullivan,
A.
Teitelbaum
(2013)
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
ClinicoEconomics and Outcomes Research: CEOR, 5
-
Pamela
Agovino,
Stephanie
Hill
(2019)
Cancer incidence and mortality
Health at a Glance: Europe
-
J.
Amdahl,
José
Diaz,
Arati
Sharma,
Jinhee
Park,
D.
Chandiwana,
T.
Delea
(2017)
Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
PLoS ONE, 12
-
R.
Mistry,
J.
May,
G.
Suri,
K.
Young,
D.
Brixner,
G.
Oderda,
J.
Biskupiak,
D.
Tang,
S.
Bhattacharyya,
Dinesh
Mishra,
D.
Bhattacharyya,
Anand
Dalal
(2018)
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
Journal of Managed Care & Specialty Pharmacy, 24
-
G.
Mickisch,
M.
Gore,
B.
Escudier,
G.
Procopio,
S.
Walzer,
M.
Nuijten
(2009)
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
British Journal of Cancer, 102
-
Joseph
Hill
(2013)
United States Life Tables
-
B.
Durkee,
Y.
Qian,
E.
Pollom,
M.
King,
S.
Dudley,
J.
Shaffer,
D.
Chang,
I.
Gibbs,
J.
Goldhaber-Fiebert,
K.
Horst
(2016)
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 9
-
H.
Maase,
S.
Hansen,
J.
Roberts,
L.
Dogliotti,
T.
Oliver,
M.
Moore,
I.
Bodrogi,
P.
Albers,
A.
Knuth,
C.
Lippert,
P.
Kerbrat,
P.
Rovira,
P.
Wersåll,
S.
Cleall,
D.
Roychowdhury,
I.
Tomlin,
C.
Visseren-Grul,
P.
Conte
(2000)
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 17
-
Martin
Cowie
(2015)
National Institute for Health and Care Excellence.
European heart journal, 36 4
-
(2002)
World Health Organization. The world health report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization
-
X.
Gu,
Q.
Zhang,
Y.
Chu,
Yi-Yang
Zhao,
Yan-Jun
Zhang,
D.
Kuo,
B.
Su,
Bin
Wu
(2019)
Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lung cancer, 127
-
X.
Wan,
L.
Peng,
Jin-An
Ma,
Yuanjian
Li
(2017)
Economic evaluation of nivolumab as a second‐line treatment for advanced renal cell carcinoma from US and Chinese perspectives
Cancer, 123
-
H.
Smith,
Christen
Haygood,
R.
Arend,
C.
Leath,
J.
Straughn
(2015)
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Gynecologic oncology, 139 1
-
Jonathan
Samet,
Neal
Benowitz
(2020)
Food and Drug Administration
Definitions
-
P.
Petrou
(2018)
A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer
Expert Review of Pharmacoeconomics & Outcomes Research, 18
-
E.
Soto-Pérez-de-Celis,
P.
Aguiar,
M.
Cordón,
Y.
Chávarri-Guerra,
G.
Lopes
(2019)
Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
Journal of the National Comprehensive Cancer Network : JNCCN, 17 6
-
Bin
Wu,
X.
Gu,
Q.
Zhang
(2017)
Cost‐Effectiveness of Osimertinib for EGFR Mutation–Positive Non–Small Cell Lung Cancer after Progression following First‐Line EGFR TKI Therapy
Journal of Thoracic Oncology, 13
-
(2020)
EV101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma
-
T.
Powles,
J.
Rosenberg,
G.
Sonpavde,
Y.
Loriot,
I.
Durán,
Jae-Lyun
Lee,
N.
Matsubara,
C.
Vulsteke,
D.
Castellano,
Chunzhang
Wu,
M.
Campbell,
M.
Matsangou,
D.
Petrylak
(2021)
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
The New England journal of medicine
-
S.
Liou,
J.
Stephens,
K.
Carpiuc,
W.
Feng,
M.
Botteman,
J.
Hay
(2007)
Economic Burden of Haematological Adverse Effects in Cancer Patients
Clinical Drug Investigation, 27
-
M.
Sarfaty,
M.
Leshno,
N.
Gordon,
Assaf
Moore,
V.
Neiman,
E.
Rosenbaum,
D.
Goldstein
(2017)
Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.
European urology, 73 4
-
Siwei
Zhang,
K.
Sun,
R.
Zheng,
H.
Zeng,
Shaoming
Wang,
Ru
Chen,
Wenqiang
Wei,
Jie
He
(2021)
Cancer incidence and mortality in China, 2015
, 1
-
E.
Arias
(2019)
United States Life Tables, 2017.
National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System, 68 7
-
G.
Shi,
Sang
Park,
H.
Ren,
M.
Xue,
Xiao-lin
Lu,
P.
Dong,
Xin
Gao
(2018)
Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
Journal of Medical Economics, 21
-
M.
Georgieva,
J.
Lima,
P.
Aguiar,
G.
Lopes,
B.
Haaland
(2018)
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
Lung cancer, 124
-
S.
Rosso,
R.
Zanetti
(2014)
Quality of information and cancer care planning in China: a commentary to the report of cancer incidence and mortality in China.
Annals of translational medicine, 2 7
-
E.
Hill
(1948)
With the WHO in China
American Journal of Nursing, 48
-
M.
Wong,
M.
Wong,
Franklin
Fung,
Colette
Leung,
Wilson
Cheung,
W.
Goggins,
C.
Ng
(2018)
The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection
Scientific Reports, 8
-
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924
-
FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic journals.sagepub.com/home/tam urothelial cancer
-
P.
Challita-Eid,
Daulet
Satpayev,
Peng
Yang,
Z.
An,
K.
Morrison,
Y.
Shostak,
A.
Raitano,
R.
Nadell,
Wendy
Liu,
Dawn
Lortie,
L.
Capo,
Alla
Verlinsky,
Monica
Leavitt,
Faisal
Malik,
H.
Aviña,
Claudia
Guevara,
N.
Dinh,
S.
Karki,
B.
Anand,
D.
Pereira,
I.
Joseph,
F.
Doñate,
K.
Morrison,
D.
Stover
(2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Cancer research, 76 10
-
M.
Hoyle,
W.
Henley
(2011)
Improved curve fits to summary survival data: application to economic evaluation of health technologies
BMC Medical Research Methodology, 11
-
Jun
Zhu,
Wei
He,
M.
Ye,
J.
Fu,
Y.
Chu,
Yi-Yang
Zhao,
Yan-Jun
Zhang,
D.
Kuo,
Bin
Wu
(2018)
Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.
Future oncology, 14 27
-
Bin
Wu,
Q.
Zhang,
Jie
Sun
(2018)
Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
Journal for Immunotherapy of Cancer, 6
-
SEER Cancer Stat Facts
-
Yingjie
Zhang,
Xiaohui
Zeng,
Haijun
Deng,
F.
Ma,
Ye
Peng,
Lidan
Yi,
Chongqing
Tan,
L.
Peng
(2019)
Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2- Metastatic Breast Cancer From the US and Chinese Perspectives.
Clinical therapeutics, 41 6
-
T.
Younis,
D.
Rayson,
S.
Jovanović,
C.
Skedgel
(2016)
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
Breast Cancer Research and Treatment, 159
-
Guide to the methods of technology appraisal
-
D.
Vanness,
James
Lomas,
Hannah
Ahn
(2020)
A Health Opportunity Cost Threshold for Cost-Effectiveness Analysis in the United States
Annals of Internal Medicine, 174